VOR
Income statement / Annual
Last year (2025), Vor Biopharma Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Vor Biopharma Inc's net income was -$695.98 M.
See Vor Biopharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$3.49 M
|
$8.96 M
|
$0.00
|
$0.00
|
$91.00 K
|
$20.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
-$3.49 M
|
-$8.96 M
|
$0.00
|
$0.00
|
-$91.00 K
|
-$20.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$321.53 M
|
$93.31 M
|
$94.32 M
|
$64.55 M
|
$47.53 M
|
$31.62 M
|
$6.20 M
|
$2.43 M
|
| General & Administrative Expenses |
$50.11 M
|
$27.88 M
|
$31.72 M
|
$0.00
|
$21.49 M
|
$11.75 M
|
$0.00
|
$427.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$50.11 M
|
$27.88 M
|
$31.72 M
|
$19.91 M
|
$21.49 M
|
$11.75 M
|
$4.13 M
|
$427.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
-$3.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$371.64 M
|
$121.19 M
|
$122.54 M
|
$84.46 M
|
$69.02 M
|
$43.37 M
|
$10.33 M
|
$2.86 M
|
| Cost And Expenses |
$371.64 M
|
$121.19 M
|
$126.04 M
|
$93.42 M
|
$69.02 M
|
$43.37 M
|
$10.42 M
|
$2.86 M
|
| Interest Income |
$5.87 M
|
$4.27 M
|
$8.17 M
|
$1.32 M
|
$119.00 K
|
$29.00 K
|
$154.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$608.00 K
|
$1.00 M
|
| Depreciation & Amortization |
$2.89 M
|
$3.53 M
|
$3.49 M
|
$8.96 M
|
$1.43 M
|
$605.00 K
|
$91.00 K
|
$20.00 K
|
| EBITDA |
-$368.76 M |
-$117.66 M |
-$114.37 M |
-$83.13 M |
-$67.58 M |
-$42.76 M |
-$10.14 M |
-$2.84 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$324.34 M
|
$4.27 M
|
$8.17 M
|
$1.32 M
|
$119.00 K
|
$29.00 K
|
-$422.00 K
|
-$1.29 M
|
| Income Before Tax |
-$695.98 M
|
-$116.91 M
|
-$117.86 M
|
-$92.09 M
|
-$68.90 M
|
-$43.34 M
|
-$10.84 M
|
-$4.15 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$695.98 M
|
-$116.91 M
|
-$117.86 M
|
-$92.09 M
|
-$68.90 M
|
-$43.34 M
|
-$10.84 M
|
-$4.15 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-70.5 |
-34 |
-35 |
-46.6 |
-37.8 |
-26.6 |
-6.2 |
-14.6 |
| EPS Diluted |
-70.5 |
-34 |
-35 |
-46.6 |
-37.8 |
-26.6 |
-6.2 |
-14.6 |
| Weighted Average Shares Out |
$9.87 M
|
$3.44 M
|
$3.36 M
|
$1.98 M
|
$1.86 M
|
$1.86 M
|
$1.86 M
|
$283.02 K
|
| Weighted Average Shares Out Diluted |
$9.87 M
|
$3.44 M
|
$3.36 M
|
$1.98 M
|
$1.86 M
|
$1.86 M
|
$1.86 M
|
$283.02 K
|
| Link |
|
|
|
|
|
|
|
|
